PHATHOM PHARMACEUTICAL

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

28 May 2024 07:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting

15 May 2024 07:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

09 May 2024 07:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024

29 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

03 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

26 Mar 2024 07:00:05 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

07 Mar 2024 07:00:50 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024

29 Feb 2024 07:00:49 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients

13 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

31 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital

14 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

06 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

28 Nov 2023 07:00:28 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates

09 Nov 2023 07:00:01 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults

01 Nov 2023 16:00:26 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

30 Oct 2023 07:00:38 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

25 Oct 2023 07:01:03 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD

26 Sep 2023 07:01:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

05 Sep 2023 07:00:01 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application

21 Aug 2023 07:00:00 By Nasdaq GlobeNewswire